 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Findings Reported in Cancer Research SALT LAKE CITY, Oct. 1 /PRNewswire/ -- Researchers from Myriad Genetics have discovered that a gene called MKK4 (Mitogen-Activated Protein Kinase Kinase 4), may perform a major role as a tumor suppressor. The findings, published in today"s issue of the journal Cancer Research, suggest that the cell signal transduction gene is important in the process of preventing tumors from initially forming. The MKK4 gene, involved in colon, breast, pancreatic and testicular cancers, is believed to signal a cell to stop growing and to proceed through routine elimination by programmed cell death, or apoptosis. If damaged, the MKK4 gene can no longer perform it"s role of preventing cells from dividing out of control. By circumventing apoptosis, cells become cancerous, progressing to form malignant tumors. Myriad believes further investigation may demonstrate that cell signal transduction is a significant new pathway for cancer research. Previously, the MKK4 gene was only suspected of playing a minor role in cell regulation. The new report promotes the gene to an elite group of fewer than two dozen known tumor suppressors, performing a task so essential that without it, the process of cancer progression can begin. "As a cell regulatory control pathway gene, MKK4 represents an intriguing target for antitumor therapeutic development", said Dr. David Teng, the paper"s co-leading author along with Dr. William Perry, both of Myriad Genetics. "If a damaged MKK4 gene"s function could be restored through gene replacement or augmentation, one primary step potentially leading to cancer might be eliminated." The cancer genetics group at Myriad, previously responsible for discoveries of the BRCA1 and BRCA2 breast and ovarian cancer genes as well as the MMAC1 brain and many other cancers gene will proceed with development of the diagnostic and therapeutic potential of the MKK4 gene. Myriad Genetics, Inc., based in Salt Lake City, is a genomics company and genetic testing company focused on the discovery and commercialization of genes involved in major common disorders, including cancer, cardiovascular disease and central nervous system disorders. The Company is involved in strategic alliances with Schering-Plough, Novartis, Bayer and Eli Lilly and Co. Myriad"s news releases are available on the corporate website at www.myriad.com. The discussion in this news release includes forward-looking statements based on management"s current expectations. Factors that could cause future results to differ materially from such expectations include: intense competition related to the discovery of disease-related genes; the Company"s limited marketing and sales experience and the risk that BRACAnalysis(TM) and other tests which the Company develops may not be able to be marketed at acceptable prices or receive commercial acceptance in the Company"s target markets; uncertainty as to whether there will exist adequate reimbursement for the Company"s service from the government, private healthcare insurers and third-party payers; and uncertainties as to the extent of future government regulation of the Company"s business. SOURCE Myriad Genetics -0- 10/1/97 /CONTACT: William A. Hockett, Director of Corporate Communications of Myriad Genetics, Inc., 801-584-3600/ CO: Myriad Genetics ST: Utah IN: MTC SU: | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |